Hypervision Surgical, a King's College London spinout that makes hyperspectral imaging systems for surgery, raised a £17m (about $23m) Series A round announced on 29 April 2026.
Heal Capital led the round. Angelini Ventures, IP Group and Daycrest took part as new investors, and existing backers HERAN Partners, Redalpine, LifeX Ventures and ZEISS Ventures put in more money. A fund managed by SAGES Ingenuity, the for-profit innovation arm of the Society of American Gastrointestinal and Endoscopic Surgeons, made a strategic investment, as did the charity Macmillan Cancer Support. The company did not disclose a valuation or earlier funding amounts.
Michael Ebner, chief executive and co-founder, said in the announcement: "This Series A marks a major milestone in our mission to power surgical intelligence through hyperspectral vision."
“This Series A marks a major milestone in our mission to power surgical intelligence through hyperspectral vision.”Michael Ebner, CEO and co-founder, Hypervision Surgical
What Hypervision does
The company's platform, which it calls Hyperspectral Intelligence, combines on-chip spectral sensing, patented AI analysis and a cloud-scalable architecture. According to Startup Business, it turns light-spectrum data into real-time measures of tissue physiology, such as blood composition and oxygenation, to support surgeons during an operation without contact or interrupting the procedure.
Its first commercial product is HYPERSNAP, a real-time hyperspectral imaging system. The company says it is UK-certified and cleared by the US Food and Drug Administration for open and minimally invasive general surgery. Startup Business added that it runs on Nvidia's IGX edge AI architecture and was selected for the FDA's Safer Technologies Program.
The company says HYPERSNAP has been used in more than 170 procedures at three UK NHS trusts, including more than 60 colorectal procedures at St Thomas' Hospital.
Founders and origins
Hypervision was founded as a spinout from King's College London, within the London Institute for Healthcare Engineering and the St Thomas' MedTech ecosystem. Besides Ebner, who was a post-doctoral researcher at King's when the company started, the co-founders listed by the university are Professor Tom Vercauteren, Professor Jonathan Shapey and Sebastien Ourselin, head of the School of Biomedical Engineering and Imaging Sciences.
Sir Bashir Al-Hashimi, vice president for research and innovation at King's, said the company is an example of how ecosystems can speed the translation of research into commercial success.
What the money is for
The company said the funding will speed commercial deployment, widen clinical adoption across more sites in the UK, Europe and the US, and develop next-generation hyperspectral sensing technology, co-developed with imec, into a scalable, cloud-enabled surgical intelligence platform.
Startup Business reported that Tanja Dowe, managing director of Angelini Ventures, the corporate venture arm of Angelini Industries, and Rick Mangat, founder of Novadaq, will join Hypervision's board. Christian Lautner, founding managing partner at Heal Capital, said surgical AI built on conventional cameras has made impressive progress but ultimately faces a ceiling.
The company plans to integrate the platform into laparoscopic, robotic, microscopic and endoscopic systems, Startup Business said. Medtech Innovator, citing Sky News, also reported the £17m figure and the investor list.